Term
|
Definition
| Anticholinergic, bronchodilator |
|
|
Term
|
Definition
| Inhibits interaction of acetylcholine at receptor sites of bronchial smooth muscle, resulting in decreased cyclic guanosine monophosphate and bronchodilation. |
|
|
Term
|
Definition
| Persistent bronchospasm, COPD exacerbation. |
|
|
Term
|
Definition
| Hypersensitivity to ipratropium, atropine, alkaloids, peanuts. |
|
|
Term
| Adverse reactions/side effects |
|
Definition
| Headache, dizziness, nervousness, fatigue, tremor, blurred vision, cough, dyspnea, worsening of copd symptoms, tachycardia, palpitations, flushing, MI, dry mouth, nausea, vomiting, GI distress |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Aerosol 18 ug/actuation. 500 ug/mL of a .02% solution for nebulaized inhalation. |
|
|
Term
Dosage and administration
Adult & pediatrics |
|
Definition
250-500 ug via inhalation with hand-held nebulizer every 20 minutes up to 3 times
Same with pediatrics |
|
|
Term
|
Definition
Onset: 1-3 minutes.
Peak: 90-120 minutes
Duration: 4-6 hours |
|
|
Term
|
Definition
| Pregnancy safety: Category B. When used in combination with beta-agonists, the beta-agonist is always administered first with a five minute wait before administering ipratropium. Shake well before use. Use with caution in patients with urinary retention. |
|
|
